Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Amgen, Inc. (AMGN) Price & Performance

Abeona Therapeutics IncTrade
Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Amgen, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 532.2× Abeona Therapeutics Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOAMGN
Market Cap
$421.19M$224.14B
Sector
HealthHealth
52-Week High
$7.45$417.20
52-Week Low
$4.17$271.18
Enterprise Value
$276.10M$267.45B
Dividend Yield
2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN